(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 24 April 2003 (24.04.2003)

(10) International Publication Number WO 03/033009 A3

(51) International Patent Classification7: A61K 38/55, 39/395, G01N 33/68, A61P 29/00

PCT/IB02/05797 (21) International Application Number:

10 July 2002 (10.07.2002) (22) International Filing Date:

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

10 July 2001 (10.07.2001) US 60/304,461 60/304,490 US 10 July 2001 (10.07.2001) 60/305,182 13 July 2001 (13.07.2001) US

(71) Applicant (for all designated States except US): OMNIO AB [SE/SE]; Villavagen 1, S-90187 Umea (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): NY, Tor [SE/SE]; Villavagen 1, s-90336 Umea (SE). HOLMDAHL, Rikard [SE/SE]; Siriusgatan 2, S-224 57 (SE). **LI, Jinan** [CN/SE]; Pedagoggrand 1D-206, S-90730 Umea (SE).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

with international search report

(88) Date of publication of the international search report: 20 November 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL DRUG TARGETS FOR ARTHRITIS

(57) Abstract: Novel drug targets for the treatment or prevention of arthritis are provided. Screening methods for inhibitors of the plasminogen-activation pathway, such as, for example, antagonists or inhibitors of the urokinase-type okasnubigeb actuvatir (uPA), plasminogen-activator tzpe 1 (PAI-1), the urokinase activator receptor (uPAR), and plasmin, are used to ientify novel drugs for treating or preventing the progression of arthritis. Such screening methods, or methods for evaluating whether a drug is useful for treating or preventing arthritis, can also be conducted in animal models described herein. Methods of treating or preventing such diseases are also provided.

al Application No Inte PCT/IB 02/05797

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K38/55 A61K39/395 A61P29/00 G01N33/68

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) I PC $\,\,^7$ A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ

	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the	e relevant passages	Relevant to claim No.
Х	WO 98 24474 A (NIELSEN JOHN RO;BRUENNER NILS (DK); STEPHENS DANOE) 11 June 1998 (1998-06-1	ROSS (DK);	1,2,7,8, 12-17, 29-31, 46,47
Y	claims 1,25,29,61-63	18-22, 24,25, 27, 32-40, 43-45	
χ Furt	her documents are listed in the continuation of box C.	X Patent family members	are listed in annex.
		<u></u>	
"A" docume consid "E" earlier filing c "L" docume which citatio	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date and which may throw doubts on priority claim(s) or is cited to establish the publication date of another nor other special reason (as specified) ent referring to an oral disclosure, use, exhibition or	"T" later document published aft or priority date and not in cited to understand the prin invention "X" document of particular relevicannot be considered nove involve an inventive step w "Y" document of particular relevicannot be considered to inventive step w cannot be considered	ter the international filing date onflict with the application but aciple or theory underlying the ance; the claimed invention of cannot be considered to the the document is taken alone
"A" docume consider "E" earlier of filing of "L" docume which citatio "O" docume other "P" docume"	ent defining the general state of the art which is not defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date on the which may throw doubts on priority claim(s) or is cited to establish the publication date of another nor other special reason (as specified)	"T" later document published aft or priority date and not in cocited to understand the print invention "X" document of particular relevicannot be considered nove involve an inventive step w "Y" document of particular relevicannot be considered to involve an inventive step w "Y" document of particular relevicannot be considered to involve an inventive step w "Y" document of particular relevicannot be considered to involve an inventive step w	ter the international filing date onflict with the application but ciple or theory underlying the ance; the claimed invention of the considered to the hen the document is taken alone ance; the claimed invention wolve an inventive step when the tone or more other such docueing obvious to a person skilled
"A" docume consider iffing consideration in the	ent defining the general state of the art which is not dered to be of particular relevance document but published on or after the international date ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another n or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but	"T" later document published aft or priority date and not in c cited to understand the prir invention "X" document of particular releving cannot be considered nove involve an inventive step w "Y" document of particular releving cannot be considered to inventive step w understand to combined with ments, such combination b in the art.	ter the international filing date conflict with the application but niciple or theory underlying the cance; the claimed invention of the considered to then the document is taken alone ance; the claimed invention volve an inventive step when the none or more other such docueing obvious to a person skilled me patent family
"A" docume consider filing of the citatio of the country of the citatio of the country of the citatio of the citation of the country of the citation of	ant defining the general state of the art which is not dered to be of particular relevance document but published on or after the international late ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another no rother special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filing date but han the priority date claimed	"T" later document published aft or priority date and not in cocited to understand the prir invention "X" document of particular relevations and be considered nove involve an inventive step w "Y" document of particular relevations of the considered to involve an inventive step w cannot be considered to involve and the combined with ments, such combined with ments, such combination b in the art. "&" document member of the sa	ter the international filing date conflict with the application but niciple or theory underlying the cance; the claimed invention of the considered to then the document is taken alone ance; the claimed invention volve an inventive step when the none or more other such docueing obvious to a person skilled me patent family

Int. I Application No PCT/IB 02/05797

Category Citation of document, with indication, where appropriate, of the relevant passages X W0 92 07083 A (CANCERFORSKNINGSFONDET AF 1989) 30 April 1992 (1992-04-30) Claims 53-55,58,62,63 PP 0 835 931 A (DAIICHI PURE CHEMICALS CO LTD) 15 April 1998 (1998-04-15) page 4, line 14 - line 17 page 4 -page 5; example 1 TEWODROS WEZENET ET AL: "Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease manifestations."	Relevant to claim No. 1,4,5, 10, 12-17, 23,26, 28,31, 41,42, 46,47 18-20, 27,32-34
X WO 92 07083 A (CANCERFORSKNINGSFONDET AF 1989) 30 April 1992 (1992-04-30) claims 53-55,58,62,63 Y EP 0 835 931 A (DAIICHI PURE CHEMICALS CO LTD) 15 April 1998 (1998-04-15) page 4, line 14 - line 17 page 4 -page 5; example 1 Y TEWODROS WEZENET ET AL: "Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease	1,4,5, 10, 12-17, 23,26, 28,31, 41,42, 46,47
claims 53-55,58,62,63 Claims 53-55,58,62,63 EP 0 835 931 A (DAIICHI PURE CHEMICALS CO LTD) 15 April 1998 (1998-04-15) page 4, line 14 - line 17 page 4 -page 5; example 1 TEWODROS WEZENET ET AL: "Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease	10, 12-17, 23,26, 28,31, 41,42, 46,47 18-20, 27,32-34
LTD) 15 April 1998 (1998-04-15) page 4, line 14 - line 17 page 4 -page 5; example 1 TEWODROS WEZENET ET AL: "Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease	27,32-34
LTD) 15 April 1998 (1998-04-15) page 4, line 14 - line 17 page 4 -page 5; example 1 TEWODROS WEZENET ET AL: "Streptokinase activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease	27,32-34
activity among group A streptococci in relation to streptokinase genotype, plasminogen binding, and disease	35-37
MICROBIAL PATHOGENESIS, vol. 18, no. 1, 1995, pages 53-65, XP002246934 ISSN: 0882-4010 page 61, paragraph 2	
JENSEN S ET AL: "The role of beta-strand 5A of plasminogen activator inhibitor-1 in regulation of its latency transition and inhibitory activity by vitronectin" BIOCHIMICA ET BIOPHYSICA ACTA. PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, ELSEVIER, AMSTERDAM,, NL, vol. 1597, no. 2, 3 June 2002 (2002-06-03), pages 301-310, XP004361034 ISSN: 0167-4838 page 302, paragraph 2.3 -page 303, paragraph 2.4	21,22, 24,25, 38-40, 43-45
RONDAY H K ET AL: "Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis." BRITISH JOURNAL OF RHEUMATOLOGY, vol. 36, no. 1, 1997, pages 9-15, XP002246935 ISSN: 0263-7103 page 13, Discussion	1,4,5,7, 8,10, 12-15, 46,47
US 4 595 674 A (SCHMUCK RAINER ET AL) 17 June 1986 (1986-06-17) column 13, line 1 - line 19	1,7,8, 46,47
-/	

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

Inter nal Application No
PCT/IB 02/05797

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevan	t passages	Relevant to claim No.
Х	US 6 051 576 A (CYNKOWSKA GRAZYNA 18 April 2000 (2000-04-18) column 18 -column 20; example 20	ET AL)	1,4,7,9, 46,47
A	US 5 164 482 A (HOERLEIN DIETRICH 17 November 1992 (1992-11-17) column 1, line 17 - line 19 column 1, line 44-51	ET AL)	1-15
,			

national application No. PCT/IB 02/05797

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. χ	Claims Nos.: 1-15 because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210
2. X	Claims Nos.: 1-6, 46-47 (PARTIALLY) because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: see FURTHER INFORMATION sheet PCT/ISA/210
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 1-15

Claims 1-15 relate to methods of treatment of the human or animal body by surgery or by therapy or diagnostic methods practiced on the human or animal body (Rule 39.1(iv)). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compounds or compositions.

Continuation of Box I.2

Claims Nos.: 1-6, 46-47 (PARTIALLY)

Present claims 1-6 and 46-47 relate to the use of an agent defined by reference to a desirable characteristic or property, namely that inhibits at least one member selected from the group consisting of plasmin, plasminogen, urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen-activator inhibitor type 1. The claims cover all agents having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and disclosure within the meaning of Article 5 PCT for only a very limited number of such agents. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the agent by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible.

Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the agent exemplified in the description (i.e. aprotinin). The general aspects of the invention have also been searched to some extent.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Information on patent family members

Internal Application No
PCT/IB 02/05797

					3 02/03/3/
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9824474	A	11-06-1998	AU WO EP US	5187698 A 9824474 A1 0942746 A1 2002099004 A1	29-06-1998 11-06-1998 22-09-1999 25-07-2002
WO 9207083	А	30-04-1992	AT AU CA DE DE WO EP ES US	219791 T 661978 B2 8757291 A 2094276 A1 69133049 D1 69133049 T2 9207083 A1 1281404 A2 0574391 A1 2179036 T3 6113897 A	15-07-2002 17-08-1995 20-05-1992 19-04-1992 01-08-2002 02-01-2003 30-04-1992 05-02-2003 22-12-1993 16-01-2003 05-09-2000
EP 0835931	A	15-04-1998	JP JP AU EP US WO	9009997 A 9009998 A 6138396 A 0835931 A1 5879923 A 9701631 A1	14-01-1997 14-01-1997 30-01-1997 15-04-1998 09-03-1999 16-01-1997
US 4595674	A	17-06-1986	DE AU AU CA DE DK EP ES GR HU IE JP JP KR ZA	3339693 A1 34989 T 560584 B2 3000184 A 1238000 A1 3471940 D1 60993 A 369284 A 0132732 A2 8601858 A1 82265 A1 34515 A2 199880 B 57628 B1 72494 A 1954612 C 6086479 B 60056999 A 8904784 B1 209001 A 8405824 A	15-05-1985 15-06-1988 09-04-1987 31-01-1985 14-06-1988 14-07-1988 27-05-1993 29-01-1985 13-02-1985 01-03-1986 13-12-1984 28-03-1985 28-03-1990 10-02-1993 29-02-1988 28-07-1995 02-11-1994 02-04-1985 27-11-1989 24-02-1989
US 6051576	A	18-04-2000	US AU AU CA EP JP WO	5965590 A 705226 B2 6254594 A 2182228 A1 0740650 A1 9509151 T 9520567 A1	12-10-1999 20-05-1999 15-08-1995 03-08-1995 06-11-1996 16-09-1997 03-08-1995
US 5164482	Α	17-11-1992	DE AT AU AU	3930522 A1 113074 T 632361 B2 6245390 A	21-03-1991 15-11-1994 24-12-1992 21-03-1991

Information on patent family members

In al Application No
PCT/IB 02/05797

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
US 5164482	Α	CA	2025070 A1	14-03-1991
		DD	299311 A5	09-04-1992
		DE	59007498 D1	24-11-1994
		DK	419878 T3	21-11-1994
		EP	0419878 A1	03-04-1991
		ES	2062235 T3	16-12-1994
		FI	104724 B1	31-03-2000
		HU	62031 A2	29-03-1993
		ΙL	95618 A	12-09-1996
		JP	2916228 B2	05-07-1999
		JP	3197496 A	28-08-1991
		KR	169976 B1	01-02-1999
		US	5231010 A	27-07-1993
		ZA	9007266 A	31-07-1991

Form PCT/ISA/210 (patent family annex) (July 1992)